Canada 2020 in review: Cannabis and Covid-19 While these 365 days will be defined by a pandemic, it was also a year legal reform spread, sales soared and capital markets rallied Jared GnamDecember 31, 2020
Canada The best and worst of Canadian legal cannabis in 2020 As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices muggleheadDecember 31, 2020
Psychedelics 2020’s top 5 advancements in psychedelics With major research, legal reform, and more than 20 firms going public, it was major year for the re-emerging field Jared GnamDecember 30, 2020
International A record 3,627 cannabis studies conducted in 2020 From CBD drivers to stoner rats, legal reform continues to push weed research to an all-time high Jared GnamDecember 28, 2020
Extraction Canopy’s GW Pharma lawsuit could be trouble for US extractors Canopy has a fair shot at winning its suit against GW, but the case might not have a widespread effect on US pot extractors,... Jared GnamDecember 24, 2020
Analysis Instagram’s cannabis restrictions aren’t about the law While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe Veronica IrwinDecember 24, 2020
Industry update MagicMed attracts investors to advance library of psychedelic derivatives After raising $8.1M, the Calgary company filed 12 patents and launched a candidate selection program for novel psychedelic mental health treatments Jared GnamDecember 23, 2020
Analysis What happened to Canada’s ibogaine clinics? Following a surge of interest, ibogaine therapy in the country disappeared. But recent signs show regulators are warming to the promising plant Suzannah WeissDecember 23, 2020
Canada Health Canada delivers cannabis data dump for the holidays The federal agency reports a rise in national pot use and medical cannabis registrations in 2020, as well as new enforcement data Jared GnamDecember 22, 2020
Industry update Canopy Growth inks $297M deal to give up stake in Canopy Rivers The Canadian weed giant is cutting ties with its venture capital firm that will have the freedom to focus on the U.S. market Jared GnamDecember 21, 2020